ロード中...
4CPS-042 Apremilast in psoriatic arthritis and psoriasis: a case report
BACKGROUND: Apremilast is an orally-active small molecule which inhibits phosphodiesterase-4 (PDE4). Clinical trials have demonstrated its efficacy and safety in psoriatic arthritis (PsA) and psoriasis (PsO). PsA is a chronic inflammatoryarthropathy that affects joints accompanied by inflammation of...
保存先:
| 出版年: | Eur J Hosp Pharm |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Group
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535203/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.133 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|